Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SYNCOM FORMULATIONS Gains 16%; BSE HEALTHCARE Index Down 0.4%
Mon, 9 Sep 12:17

SYNCOM FORMULATIONS Gains 16%; BSE HEALTHCARE Index Down 0.4%Image source: asbe/www.istockphoto.com

SYNCOM FORMULATIONS share price has zoomed 16% and is presently trading at Rs 26.9.

Meanwhile, the BSE HEALTHCARE index is at 43,305.0 (down 0.4%).

Among the top gainers in the BSE HEALTHCARE index today are Jubilant Pharmova (up 8.4%) and HIKAL CHEMIC (up 7.1%).

GRANULES INDIA (down 3.5%) and MAX HEALTHCARE INSTITUTE (down 2.2%) are among the top losers today.

Over the last one year, SYNCOM FORMULATIONS has moved up from Rs 8.8 to Rs 26.9, registering a gain of Rs 18.2 (up 207.5%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,163.1 to 43,305.0, registering a gain of 53.8% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were SUVEN PHARMACEUTICALS (up 133.1%), Jubilant Pharmova (up 123.0%) and Glenmark Pharma (up 114.4%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 81,231.1 (up 0.1%).

The top gainers among the BSE Sensex today are Hindustan Unilever (up 1.7%) and ICICI Bank (up 1.0%). The most traded stocks in the BSE Sensex are Tata Steel and SBI.

In the meantime, NSE Nifty is at 24,852.0 . ONGC and Hindalco are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,780.3 to 81,231.1, registering a gain of 15,450.8 points (up 23.5%).

SYNCOM FORMULATIONS Financial Update...

SYNCOM FORMULATIONS net profit grew 73.6% YoY to Rs 76 million for the quarter ended June 2024, compared to a profit of Rs 44 million a year ago. Net sales rose 45.8% to Rs 873 million during the period as against Rs 598 million in April-June 2023.

For the year ended March 2023, SYNCOM FORMULATIONS reported 1.4% increase in net profit to Rs 201 million compared to net profit of Rs 198 million during FY22. Revenue of the company grew 2.1% to Rs 2,243 million during FY23.

The current Price to earnings ratio of SYNCOM FORMULATIONS, based on rolling 12 month earnings, stands at 88.7.


Equitymaster requests your view! Post a comment on "SYNCOM FORMULATIONS Gains 16%; BSE HEALTHCARE Index Down 0.4%". Click here!